Application of dimethyl carbonate as chronic obstructive pulmonary disease diagnostic marker
By detecting dimethyl carbonate in exhaled breath and utilizing thermal desorption-full two-dimensional gas chromatography-time-of-flight mass spectrometry, the problems of complex operation and lack of specificity of existing biomarkers in COPD diagnosis have been solved, achieving a simplified process and efficient diagnosis.
Patent Information
- Application Number
- CN202610490189.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-14
- Publication Date
- 2026-06-23
AI Technical Summary
Existing technologies for the diagnosis of chronic obstructive pulmonary disease (COPD) are complex to operate, have low sensitivity in detecting early mild cases, and cannot reflect disease heterogeneity. Existing biomarkers lack specificity and are difficult to meet the needs of accurate diagnosis.
Dimethyl carbonate (DMC) was used as a diagnostic biomarker in exhaled breath. The presence of DMC in exhaled breath samples was detected, and the analysis was performed using thermal desorption-two-dimensional gas chromatography-time-of-flight mass spectrometry (TD-GC×GC-TOF-MS), which simplifies the detection process and improves diagnostic efficiency.
It enables effective identification of COPD, simplifies the testing process, reduces costs, and improves the specificity and sensitivity of diagnosis, demonstrating good diagnostic efficacy.